FAMILY HYPERCHOLESTEREMIA IN KRASNODAR REGION: ISSUES AND HOW TO SOLVE THEM
Abstract
Coronary surgery and endovascular coronary interventions allowed significantly reduce mortality and an invalidization caused by sharp and chronic forms of coronary heart disease in Krasnodar Region. Searching ways for further improvement of these indicators we start paying more attention to problems of timely identification of risk factors in cases with atherosclerotic cardiovascular diseases (ACD) and their primary prevention, especially among the efficient labor pool.
From this point of view family hypercholesterolemia (SGHS) as a disease connected with a very high risk of ACD and frequently at young age, is one of the significant points of effort application for prevention of incidence and mortality from ACD. In recent years on the basis of the executed epidemiological and register researches there was a significant revision of ideas on possible prevalence of SGHS, as a result this disease is considered not to be so rare: ~ 1:200–1:250 in a general population. Low awareness among the population and physicians on SGHS in Russia and Krasnodar Region, its extremely low detection frequency, lack of information about real prevalence of this pathology lead to the fact that the correct diagnosis is very seldom verified, and modern treatment which is capable to change the course of a disease is carried out.
Modern approaches of diagnosis and treatment for SGHS are presented in this article, clinical cases from own clinical practice are described and also, we discuss possible steps on the organization of timely identification and treatment of SGHS.
About the Authors
A. M. Namitokov
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1
Russian Federation
Russian Federation
Head of cardiology department no. 2
350086, Krasnodar, 167, 1st May street
V. K. Zafiraki
Kuban State Medical University
Russian Federation
Assistant professor of Therapy Department no. 1 FAT
Russian Federation
Assistant professor of Therapy Department no. 1 FAT
V. I. Fetisova
Kuban State Medical University
Russian Federation
Clinical Resident of the Department of Cardiac Surgery and Cardiology
Russian Federation
Clinical Resident of the Department of Cardiac Surgery and Cardiology
E. D. Kosmacheva
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1;
Kuban State Medical University
Russian Federation
Dr. of Sci. (Med.), chief medical officer, Scientific Research Institute – Ochapovsky Regional Clinic Hospital no. 1, head of Department of therapy no. 1 ATF, Kuban State Medical University
Russian Federation
Dr. of Sci. (Med.), chief medical officer, Scientific Research Institute – Ochapovsky Regional Clinic Hospital no. 1, head of Department of therapy no. 1 ATF, Kuban State Medical University
References
1. Iacocca MA, Chora JR, Carrié A, Freiberger T, Leigh SE, еt al. ClinVar database of global familial hypercholesterolemia-associated DNA variants. HumMutat. 2018:39(11):1631-1640.
2. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 2003;111:1795-1803. DOI: https://doi.org/10.1172/jci200318925
3. Titov V.N., Vostrov I.A., Kaba S.I. et al. Very low density lipoprotein: pathogenesis and clinical significance. Clinical medicine. 2013;1:20-27. (In Russ.).
4. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-2472. DOI: https://doi.org/10.1093/eurheartj/ehx144
5. Benn M, Watts GF, Tybjaerg-Hansen А, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 2012;97(11):3956-3964. DOI: https://doi.org/10.1210/jc.2012-1563
6. Cuchel M, Bruckert Е, Ginsberg HN, Raal FJ, Santos RD, et al. European atherosclerosis society consensus panel on familial hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the european atherosclerosis society. Eur. Heart J. 2014;35(32):2146-2157.
7. Ershova AI, Meshkov AN, Bazhan SS, Storozhok MA, Efanov AY, et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoS One. 2017;12(7):e0181148. DOI: https://doi.org/10.1371/journal.pone.0181148
8. Ezhov MV, Sergienko IV, Duplyakov DV, Abashina OE, Kachkovskii MA, et al. Russian recommendations for the diagnosis and treatment of familial hypercholesterolemia. Atherosclerosis and dyslipidemia. 2016;4:21-29. (In Russ.).
9. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J. ClinLipidol. 2014;8(2):148-172.
10. Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, et al. Survival in homozygous familial hypercholesterolemia is determined by the on-treatment level of serum cholesterol. Eur. Heart J. 2018;39:11621168. DOI: https://doi.org/10.1093/eurheartj/ehx317
11. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis. 1999;142:105-112. DOI: https://doi.org/10.1016/s00219150(98)00200-7
12. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29:2625-2633. DOI: https://doi.org/10.1093/eurheartj/ehn422
13. Galema-Boers AM, Lenzen MJ, Engelkes SR, Sijbrands EJ, Roeters van Lennep JE. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. J. Clin Lipidol. 2018; 12(2):409-416. DOI: https://doi.org/10.1016/j.jacl.2017.12.014
14. Chhatriwalla AK, Nicholls SJ, Nissen SE. The ASTEROID trial: coronary plaque regression with highdose statin therapy. Future Cardiol. 2006;2(6):651-654. DOI: https://doi.org/10.2217/14796678.2.6.651
15. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. European Heart Journal. 2015;35:1-4.
Review
For citations:
Namitokov A.M., Zafiraki V.K., Fetisova V.I., Kosmacheva E.D. FAMILY HYPERCHOLESTEREMIA IN KRASNODAR REGION: ISSUES AND HOW TO SOLVE THEM. Innovative Medicine of Kuban. 2019;(1):57-63. (In Russ.)
Views:
383
Email this article 
